Search

Tetraethylammonium

The only marketed drug containing tetraethylammonium was a combination drug called Fosglutamina B6, but this drug has now been discontinued. … Because of its inhibitory actions at the autonomic ganglia, tetraethylammonium was thought to be a potential therapeutic vasodilator but serious toxic effects were found.

Pramipexole

It was first approved by the FDA in 1997 [L5882]. … RLS is a sleep-related disorder characterized by unpleasant sensations in the lower extremities, often accompanied by an uncontrollable urge to move the legs [A176876].

Venetoclax

Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label].

Isosulfan blue

Droperidol

It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the

Etoricoxib

It is approved in more than 60 countries worldwide but not in the US.

Insulin degludec

[A18561,A18562,A18563,A18564,A174934] Compared to available long-acting analogs such as [DB00047] and [DB01307], which have a duration of action of 20-24 hours, insulin degludec provides a consistent level … Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.

Cilnidipine

It was jointly developed by Fuji Viscera Pharmaceutical Company, Japan and Ajinomoto, Japan and approved in 1995.

Selinexor

[L7117,L7120,L10145] This condition is typically treated with high dose [bortezomib] and [dexamethasone] chemotherapy followed by an autologous stem-cell transplant. … [L10145] The use of selinexor in combination with [bortezomib] and [dexamethasone] was approved by Health Canada in June 2022 for the treatment of multiple myeloma in adult patients who have received at

Ripretinib

Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020.